Leon Chen
Overview
Leon Chen is an angel investor specializing in early-stage healthcare and life sciences ventures. He typically invests between $100,000 and $5 million in pre-seed to seed stages, focusing on sectors such as health and hospital services, biotechnology, manufacturing, and pharmaceuticals. His investment approach is characterized by a strong background in healthcare and life sciences, supporting early-stage therapeutics and manufacturing ventures. In addition to his investment activities, Leon Chen serves as the CEO and Founding Partner at 6 Dimensions Capital, a healthcare investment firm with operations in both China and the United States. He holds a PhD from the University of Louvain-La-Neuve and has conducted post-doctoral work at the Massachusetts Institute of Technology. His professional experience includes roles at McKinsey & Company, Ernst & Young, and Life Science Strategic Consulting. Leon Chen has been recognized for his contributions to the field, being named to GrowthCap’s Top 40 Under 40 Growth Investors of 2021. His leadership and collaborative work style have been instrumental in building a diverse team and identifying investment opportunities that add value to the companies he invests in.
Investment Focus
- Early-stage healthcare and life sciences ventures
Portfolio Companies
Reach Leon Chen directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Leon Chen
What sectors does Leon Chen invest in?
Leon Chen invests in Pharmaceuticals, Manufacturing, Biotech and Health & Hospital Services, and is based in California, United States. Leon Chen is listed as a angel investor in the ConnectSafely investor database.
What stage does Leon Chen invest at?
Leon Chen backs companies at Pre-Seed and Seed, writing cheques of 100K - 5M.
Which regions does Leon Chen invest in?
Leon Chen invests across United States and China.
What companies has Leon Chen invested in?
Leon Chen's portfolio includes Ignis Therapeutics, Ultivue and Viela Bio.
Last updated · Source: ConnectSafely investor database
